

1  
2 Community Acquired Rhinovirus Infection Is Associated With Changes in the Airway  
3 Microbiome

4  
5 Online Data Supplement

6  
7 Kirsten M. Kloepfer MD<sup>a</sup>, Vishal K. Sarsani MS<sup>b</sup>, Valeriy Poroyko PhD<sup>c</sup>, Wai Ming Lee PhD<sup>d</sup>,  
8 Tressa E. Pappas BS<sup>d</sup>, Theresa Kang BS<sup>d</sup>, Kristine A. Grindle BS<sup>d</sup>, Yury A. Bochkov PhD<sup>d</sup>,  
9 Sarath Chandra Janga PhD<sup>b</sup>, Robert F. Lemanske Jr. MD<sup>d,e</sup> and James E. Gern MD<sup>d,e</sup>

10  
11 From the Department of Pediatrics, Indiana University School of Medicine<sup>a</sup>, Department of  
12 Biohealth Informatics, School of Informatics and Computing, Indiana University Purdue  
13 University Indianapolis<sup>b</sup>, Department of Pediatrics, University of Chicago<sup>c</sup>, and the Departments  
14 of Pediatrics<sup>d</sup>, Medicine<sup>e</sup>, and Biostatistics and Medical Informatics<sup>f</sup>, University of Wisconsin-  
15 Madison

16  
17 Corresponding author: Kirsten M. Kloepfer MD, 705 Riley Hospital Drive, Indianapolis, IN  
18 46202. Telephone number (317) 278-7860, Fax number (317) 278-7856, and Email address:  
19 kloepfer@iu.edu

20  
21  
22

23 **Supplemental Methods**

24

25 **Recruitment and Inclusion/Exclusion Criteria**

26 The study population was recruited from the general population in Madison, Wisconsin and  
27 surrounding areas via primary care physicians, allergy and asthma specialists and advertisements  
28 in the community. The study was designed to be as inclusive as possible to reflect the general  
29 population. Any child with or without asthma, ages 4-12 years, was considered eligible for the  
30 study provided they did not have a history of prematurity, complications at birth, respiratory  
31 problems at birth or any other significant medical illness.

32 A subset of RhinoGen subjects were included in this pilot study based on the following  
33 criteria: 1) physician diagnosis of asthma per NHLBI and ATS criteria (1, 2); 2) the initial  
34 specimen tested negative for virus with an absence of cold and/or asthma symptoms for seven  
35 days prior to and four days following specimen collection; 3) the follow-up specimen tested  
36 positive for rhinovirus (and no other virus) and was the first viral infection since the initial  
37 specimen was collected; 4) the follow-up specimen was associated with either an absence of cold  
38 and asthma symptoms, or with an asthma exacerbation; and 4) enough sample remained for  
39 microbial analysis. Of the 310 eligible subjects, 29 met the above criteria, including 8 subjects  
40 who experienced an RV-associated asthma exacerbation (Supplemental Figure 1). From the 21  
41 subjects who experienced asymptomatic infections, we randomly selected 10 subjects for  
42 analysis. Of note, one subject in the asthma exacerbation group was eliminated during analysis  
43 due to insufficient DNA detection during sample processing.

44 **Symptom scoring and asthma diagnosis**

45 Children scored cold and asthma symptom severity based on a 4-point scoring system  
46 (supplemental Table 2) (3, 4) Moderate asthma exacerbations were defined as at least moderate

47 asthma symptoms (score  $\geq 2$ ) and either a decrease in PEF of at least 20% or increased use of  
48 albuterol  $\geq 2$  days, in accordance with NHLBI and ATS definitions.(1, 2) Current asthma was  
49 diagnosed at study completion based on the above criteria.

50 The asthma status of each participant was reported by their parent upon enrollment. Then,  
51 in the main RhinoGen study, we followed asthma symptoms and treatment over one year to  
52 confirm asthma status. Current asthma was diagnosed at the end of the study period based on the  
53 documented presence of one or more of the following characteristics in the previous year: (1) use  
54 of albuterol for coughing or wheezing episodes (prescribed by physician), (2) use of a daily  
55 controller medication, (3) step-up plan including use of albuterol or short-term use of inhaled  
56 corticosteroids during illness, (4) use of prednisone for asthma exacerbation, and (5) reversibility  
57 of pulmonary function tests after administration of a short-acting beta-agonist. Two separate  
58 investigators, blinded to any antecedent histories concerning viral illnesses or patterns of  
59 aeroallergen sensitization, independently evaluated each subject for the presence or absence of  
60 asthma based on the above criteria.

#### 61 Sample Analysis

62 DNA was extracted from nasal samples using the BiOstic Bacteremia DNA Isolation Kit  
63 (Mo BIO laboratories, Carlsbad, California). Specimens were multiplexed using the 515f/806r  
64 primer set that amplifies the V4–V5 region of the 16S rRNA gene (5, 6). The primers contain  
65 the appropriate Illumina adapters and the reverse primer contains a 12-base error-correcting  
66 barcode unique to each sample (7). DNA was amplified in triplicate PCR reactions using  
67 TaKaRa ExTaq enzyme mixture (Clontech). The PCR protocol was: 1 cycle of 10 minutes at 95°  
68 C followed by 30 cycles of 95° C for 30 seconds, 55° C for 1 minute, 72 °C for 1 minute and a  
69 final elongation at 72° C for 10 minutes (8). The resulting amplicons were purified with

70 UltraClean PCR Clean-Up Kit (MO BIO) and the triplicate reactions were pooled together in  
71 equimolar concentrations (7).

72 Sequencing was performed on an Illumina MiSeq (5). The resulting sequence reads were  
73 de-multiplexed using CASAVA software installed on the MiSeq Illumina sequencer producing  
74 6,042,668 sequencing tags. Separate pairs of fastq files were generated for each specimen. The  
75 splicing of forward and reverse fastq files produced an average of  $100,710 \pm 48,567$  tags per  
76 specimen.

#### 77 Sequence Quality Analysis

78 16S rRNA sequence processing and analysis was performed utilizing Mothur (v.1.33.3)  
79 software (9, 10). Raw paired-end fastq sequences of each sample were combined into contigs  
80 using make.contigs from the Mothur package which scans across the alignment and identifies  
81 any positions where the two reads disagree. To improve the quality of our data we excluded the  
82 following: 1) bases with quality score less than 25; 2) sequences with ambiguous bases; 3)  
83 sequences with a read length longer than 275 bp; and 4) duplicated sequences. SILVA-based  
84 bacterial reference alignment (release 119) was used to align the processed reads (11). Maximum  
85 homopolymer length was set to 8 and the gap characters in alignment were removed to improve  
86 the overall alignment quality. Within the Mothur package, we used the UCHIME algorithm to  
87 detect and remove chimera sequences.

#### 88 Operational Taxonomic Unit (OTU) clustering

89 For fragment quality control, we trimmed off both the undesirable 18s fragments, and the  
90 16s fragments from Archaea, chloroplasts, and mitochondria. Using the dist.seqs command,  
91 uncorrected pairwise distances between aligned DNA sequences were calculated and stored in  
92 the column formatted distance matrix. To assign sequences to respective OTUs, clustering was

93 performed using the average neighbor method at a 99% identity cut-off level. Finally,  
94 taxonomical classification for each OTU was obtained by using the classify.seqs command  
95 within the Mothur software package (10).

#### 96 Sequence Analysis

97 Rarefaction curves describing the number of OTUs observed as a function of sampling  
98 effort were generated using the sobs calculator in Mothur. Random sub-sampling was performed  
99 to address concerns of different sequencing depths across samples, affecting the rarefaction  
100 curves. To calculate significance between pre and post infection, Pearson's Chi-squared test was  
101 used. Finally, Shannon diversity and evenness and Simpson diversity and evenness indices were  
102 calculated from the sub-sampled OTU abundance data.

103 To identify if the presence of OTUs differed significantly between the subject groups,  
104 Fisher's exact test was performed. The Unifrac and Bray-Curtis distances were calculated  
105 between the community structures of the RV subjects for variation analysis. Principal  
106 coordinates (PCoA), which employs an eigenvector-based approach, was performed with the  
107 Mothur package to represent the multidimensional data of OTU abundance in three dimensions.  
108 Species-axes correlations were obtained by using the corr.axes command with the Mothur  
109 package.

#### 110 Rhinovirus abundance and microbial association analysis

111 For association analysis, individual OTUs were assigned to the lowest available  
112 taxonomy of bacteria, and OTUs not present in at least 4 samples were not included. Next, both  
113 negative (Spearman's  $\rho < -0.5$ , P-value  $< 0.05$ ) and positive (Spearman's  $\rho > 0.5$ , P-value  $< 0.05$ )  
114 Spearman rank-order correlations were calculated between OTU abundance and RV abundance.

115

116 Supplemental Table I: Demographics between subjects included in this study and the other  
 117 RhinoGen participants with asthma. *Race/ethnicity: subjects may select more than one category.*  
 118  
 119

	Children with Asymptomatic RV Infection	Children with RV-Induced Exacerbation of Asthma	Other RhinoGen Participants with Asthma	P-value
Number of subjects	10	7	150	
Age (y)	8.0 [8.0, 8.7]	6.8 [5.8, 8.1]	8.4 [6.8, 9.6]	0.23
Gender	2 F, 8 M	1 F, 6 M	52 F, 98 M	0.45
Race/ethnicity:				
White	100%	100%	87%	0.58
Black	0%	14%	13%	0.70
Hispanic or Latino	10%	0%	7%	0.74
Asian	0%	0%	4%	1.00
American Indian or Alaskan native	0%	0%	1%	1.00
Other	0%	0%	2%	1.00
Pacific Islander or Hawaiian	0%	0%	1%	1.00
Aeroallergen sensitization	70%	57%	61%	0.85
Asthma	100%	100%	100%	NA
FeNO	8.3 [7.4, 30.7]	19.2 [8.5, 41.6]	13.8 [8.0, 26.2]	0.87
Total IgE	318 [32, 497]	146 [96, 262]	125 [37, 388]	0.91

120

121 Supplemental Table II. Definition of Cold and Asthma Scores

		<b>Cold Symptoms</b>	<b>Asthma Symptoms</b>
0	Absent	None	None
1	Mild	Mild stuffy or runny nose but does not affect daily activity	Occasional cough or wheeze but does not affect daily activity
2	Moderate	Moderate stuffy or runny nose and reduced activity but does not affect sleep	Frequent cough or wheeze with some shortness of breath and reduced activity but not affecting sleep
3	Severe	Cannot breathe through the nose and not able to sleep well because of symptoms	Unable to sleep well because of symptoms

122  
 123  
 124  
 125

126 Supplemental Figure 1: Subject Inclusion

127

128

129 Supplemental Figure 2: Relative abundance at the Phylum and Genera level between RV-  
130 negative and RV-positive samples. Firmicutes  $q$ -value= $7.62 \times 10^{-6}$ ; *Dolosigranulum*  $q$ -  
131 value= $1.13 \times 10^{-8}$ ; *Moraxella*  $q$ -value= $5.5 \times 10^{-7}$ ; and unclassified OTU #1  $q$ -value= $1 \times 10^{-24}$ .

132

133

134 Supplemental Figure 3. Microbial composition of individual samples. First bar in each pair is  
135 uninfected, second bar is RV infected.

136

137

138 Supplemental Figure 4: Association networks to examine if a relationship exists between viral  
139 load and bacterial abundance. Each line represents an OTU. Green line = increase in bacterial  
140 abundance as viral load increases. Red line = decrease in abundance as viral load increases. Size  
141 of circle represents the number of sequences associated with that OTU. Node color represents the  
142 phyla associated with that OTU. Increasing viral load is associated with decreases in  
143 *Dolosigranulum*, *Corynebacterium*, *Prevotella*, *Actinomyces* and some OTUs of *Streptococcus*  
144 and *Moraxella*. However, increased viral shedding is also associated with increases in  
145 *Haemophilus* and other OTUs of *Streptococcus* and *Moraxella*. Readers should note the  
146 following: 1) the position of each node in the network is user-defined, and 2) the structure of the  
147 network does not represent any biological functions.

148

149




150 References


- 151 1. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of  
152 Asthma-Summary Report 2007. *The Journal of allergy and clinical immunology*. 2007;120(5  
153 Suppl):S94-138. Epub 2007/12/06.
- 154 2. Proceedings of the ATS workshop on refractory asthma: current understanding,  
155 recommendations, and unanswered questions. American Thoracic Society. *American journal of*  
156 *respiratory and critical care medicine*. 2000;162(6):2341-51. Epub 2000/12/09.
- 157 3. Kloepfer KM, Olenec JP, Lee WM, Liu G, Vrtis RF, Roberg KA, et al. Increased H1N1  
158 infection rate in children with asthma. *American journal of respiratory and critical care medicine*.  
159 2012;185(12):1275-9. Epub 2012/03/01.
- 160 4. Olenec JP, Kim WK, Lee WM, Vang F, Pappas TE, Salazar LE, et al. Weekly monitoring  
161 of children with asthma for infections and illness during common cold seasons. *The Journal of*  
162 *allergy and clinical immunology*. 2010;125(5):1001-6 e1. Epub 2010/04/16.
- 163 5. Fierer N, Leff JW, Adams BJ, Nielsen UN, Bates ST, Lauber CL, et al. Cross-biome  
164 metagenomic analyses of soil microbial communities and their functional attributes. *Proceedings*  
165 *of the National Academy of Sciences of the United States of America*. 2012;109(52):21390-5.  
166 Epub 2012/12/14.
- 167 6. Liu Z, Lozupone C, Hamady M, Bushman FD, Knight R. Short pyrosequencing reads  
168 suffice for accurate microbial community analysis. *Nucleic acids research*. 2007;35(18):e120.  
169 Epub 2007/09/21.
- 170 7. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et  
171 al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample.  
172 *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108  
173 Suppl 1:4516-22. Epub 2010/06/11.
- 174 8. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JJ, Knight R. Bacterial  
175 community variation in human body habitats across space and time. *Science*.  
176 2009;326(5960):1694-7. Epub 2009/11/07.
- 177 9. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-  
178 index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the  
179 MiSeq Illumina sequencing platform. *Applied and environmental microbiology*.  
180 2013;79(17):5112-20. Epub 2013/06/25.
- 181 10. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al.  
182 Introducing mothur: open-source, platform-independent, community-supported software for  
183 describing and comparing microbial communities. *Applied and environmental microbiology*.  
184 2009;75(23):7537-41. Epub 2009/10/06.
- 185 11. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, et al. SILVA: a  
186 comprehensive online resource for quality checked and aligned ribosomal RNA sequence data  
187 compatible with ARB. *Nucleic acids research*. 2007;35(21):7188-96. Epub 2007/10/20.

188  
189


Supplemental Figure 1




Phyla level analysis: RV-negative versus RV-positive




Genera Analysis: RV-negative vs. RV-positive





Paired RV-negative and RV-positive sample from each subject



	Children with Asymptomatic RV Infection	Children with RV-Induced Exacerbation of Asthma	Other RhinoGen Participants with Asthma	P-value
Number of subjects	10	7	150	
Age (y)	8.0 [8.0, 8.7]	6.8 [5.8, 8.1]	8.4 [6.8, 9.6]	0.23
Gender	2 F, 8 M	1 F, 6 M	52 F, 98 M	0.45
Race/ethnicity:				
White	100%	100%	87%	0.58
Black	0%	14%	13%	0.70
Hispanic or Latino	10%	0%	7%	0.74
Asian	0%	0%	4%	1.00
American Indian or Alaskan native	0%	0%	1%	1.00
Other	0%	0%	2%	1.00
Pacific Islander or Hawaiian	0%	0%	1%	1.00
Aeroallergen sensitization	70%	57%	61%	0.85
Asthma	100%	100%	100%	NA
FeNO	8.3 [7.4, 30.7]	19.2 [8.5, 41.6]	13.8 [8.0, 26.2]	0.87
Total IgE	318 [32, 497]	146 [96, 262]	125 [37, 388]	0.91

**Cold Symptoms****Asthma Symptoms**

---

		<b>Cold Symptoms</b>	<b>Asthma Symptoms</b>
0	Absent	None	None
1	Mild	Mild stuffy or runny nose but does not affect daily activity	Occasional cough or wheeze but does not affect daily activity
2	Moderate	Moderate stuffy or runny nose and reduced activity but does not affect sleep	Frequent cough or wheeze with some shortness of breath and reduced activity but not affecting sleep
3	Severe	Cannot breathe through the nose and not able to sleep well because of symptoms	Unable to sleep well because of symptoms